- GlobeNewswire•last monthProtalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism
CARMIEL, Israel, Sept. 07, 2016-- Protalix BioTherapeutics, Inc., announced today an oral presentation highlighting the results of the phase I/II clinical trial of PRX-102 for the treatment of Fabry disease ...
- GlobeNewswire•2 months agoProtalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease
CARMIEL, Israel, Aug. 10, 2016-- Protalix BioTherapeutics, Inc., announced today additional positive data from its phase I/II clinical trial of PRX-102 for the treatment of Fabry disease. PRX-102 is a ...
- Associated Press•2 months ago
The Carmiel, Israel-based company said it had a loss of 11 cents per share. The drug developer posted revenue of $1.8 million in the period. In the final minutes of trading on Monday, the company's shares ...
Protalix BioTherapeutics, Inc. (PLX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
|Bid||0.32 x 800|
|Ask||0.59 x 2000|
|Day's Range||0.49 - 0.51|
|52wk Range||0.48 - 1.15|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||0.99|
|Avg Vol (3m)||117,256|
|Dividend & Yield||N/A (N/A)|